TASIGNA Drug Patent Profile

When do Tasigna patents expire, and what generic alternatives are available?

Tasigna is a drug marketed by Novartis and is included in one NDA. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and thirty-one patent family members in fifty countries.

The generic ingredient in TASIGNA is nilotinib hydrochloride. There are eleven drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the nilotinib hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tasigna

A generic version of TASIGNA was approved as nilotinib hydrochloride by APOTEX on January 5^th, 2024.

Summary for TASIGNA

International Patents:	231
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	96
Clinical Trials:	68
Patent Applications:	305
Drug Prices:	Drug price information for TASIGNA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TASIGNA
What excipients (inactive ingredients) are in TASIGNA?	TASIGNA excipients list
DailyMed Link:	TASIGNA at DailyMed

See drug prices for TASIGNA

Recent Clinical Trials for TASIGNA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Xspray Pharma AB	PHASE1
Kartos Therapeutics, Inc.	Phase 1/Phase 2
Baylor College of Medicine	Phase 2

See all TASIGNA clinical trials

Pharmacology for TASIGNA

Drug Class	Kinase Inhibitor
Mechanism of Action	Bcr-Abl Tyrosine Kinase Inhibitors Cytochrome P450 2B6 Inducers Cytochrome P450 2C8 Inducers Cytochrome P450 2C8 Inhibitors Cytochrome P450 2D6 Inhibitors P-Glycoprotein Inhibitors UGT1A1 Inhibitors

Paragraph IV (Patent) Challenges for TASIGNA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TASIGNA	Capsules	nilotinib hydrochloride	50 mg	022068	1	2019-10-17
TASIGNA	Capsules	nilotinib hydrochloride	150 mg and 200 mg	022068	1	2013-11-08

US Patents and Regulatory Information for TASIGNA

TASIGNA is protected by six US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-003	Mar 22, 2018	AB	RX	Yes	No					Y
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-001	Oct 29, 2007	AB	RX	Yes	Yes					Y
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-001	Oct 29, 2007	AB	RX	Yes	Yes
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-003	Mar 22, 2018	AB	RX	Yes	No
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-003	Mar 22, 2018	AB	RX	Yes	No					Y
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-002	Jun 17, 2010	AB	RX	Yes	No					Y
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-001	Oct 29, 2007	AB	RX	Yes	Yes					Y

Expired US Patents for TASIGNA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-003	Mar 22, 2018
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-001	Oct 29, 2007
Novartis	TASIGNA	nilotinib hydrochloride	CAPSULE;ORAL	022068-002	Jun 17, 2010

International Patents for TASIGNA

When does loss-of-exclusivity occur for TASIGNA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

European Patent Office

Finland

Guatemala

Hong Kong

Hungary

Israel

Japan

Jordan

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Peru

Philippines

Poland

Russian Federation

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TASIGNA around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3984528
San Marino	P200800011	Forme cristalline di 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilammino)-benzammide
Nicaragua	200800017	FORMAS CRISTALINAS DE LA 4- METIL-N-[3-(4- METIL- IMIDAZOL-1-IL)-5- TRIFLUORO- METIL-FENIL]-3- (4- PIRIDIN- 3- IL- PIRIMIDIN- 2-IL -AMINO) BENZAMIDA
European Patent Office	2068839
Hungary	E028204
South Korea	20080027853	CRYSTALLINE FORMS OF 4-METHYL-N-[3-(4-METHYL-IMIDAZOL-1-YL)-5-TRIFLUOROMETHYL-PHENYL]-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-BENZAMIDE
Russian Federation	2445309	ИНГИБИТОРЫ ТИРОЗИНКИНАЗ (TYROSINE KINASE INHIBITORS)

Tasigna: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Tasigna (nilotinib) is a tyrosine kinase inhibitor used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML). Developed by Novartis, it targets the BCR-ABL kinase, a key driver of CML cell proliferation. This report analyzes Tasigna's market position, patent landscape, competitive environment, and projected financial performance.

What is Tasigna's Current Market Position?

Tasigna holds a significant position in the CML treatment market, primarily as a second-line therapy for patients resistant or intolerant to imatinib (Gleevec). It also has indications for newly diagnosed Philadelphia chromosome-positive CML. The drug's efficacy in achieving and maintaining deep molecular response, along with a manageable safety profile, underpins its market share.

In 2023, Tasigna continued to be a substantial revenue generator for Novartis. The drug's established presence and therapeutic utility in a chronic disease setting contribute to its sustained demand. However, the market is characterized by increasing competition from both branded and generic alternatives, alongside evolving treatment guidelines that may favor newer, potentially more targeted therapies.

What is the Patent Landscape for Tasigna?

The intellectual property surrounding Tasigna is a critical factor in its market exclusivity and subsequent revenue generation. Novartis has secured multiple patents covering the compound itself, its various crystalline forms, manufacturing processes, and specific therapeutic uses.

Key patents for Tasigna include:

• US Patent 7,169,793: Covers the nilotinib compound. Initially filed in 2001, it has been subject to various extensions, including adjustments for patent term restoration. This patent has expired in major markets, opening the door for generic competition.
• US Patent 8,198,272: This patent relates to specific crystalline forms of nilotinib, often referred to as polymorphs. These patents can extend market exclusivity by protecting specific formulations that may offer improved stability or bioavailability.
• US Patent 8,461,152: Protects methods of treating CML with nilotinib, particularly in specific patient populations or treatment scenarios.

The expiration of core compound patents has led to the introduction of generic nilotinib products in key markets. This erosion of exclusivity significantly impacts Tasigna's revenue trajectory, shifting its market dynamics from a pure originator product to one facing direct price competition. Novartis has actively defended its patents, leading to numerous legal challenges from generic manufacturers seeking to enter the market. The outcome of these legal disputes has varied by jurisdiction, influencing the timeline of generic entry and its impact on sales.

Who are Tasigna's Key Competitors?

The competitive landscape for Tasigna is multifaceted, encompassing other tyrosine kinase inhibitors (TKIs) and emerging therapies.

Established TKIs:

• Imatinib (Gleevec/Glivec): The first-generation TKI, imatinib remains a benchmark and often a first-line therapy. While Tasigna is primarily a second-line agent, the efficacy of imatinib and its generic versions continues to influence treatment decisions.
• Dasatinib (Sprycel): Developed by Bristol Myers Squibb, dasatinib is another potent TKI used in both first- and second-line CML treatment. It is often considered alongside nilotinib for patients requiring alternative therapies.
• Bosutinib (Bosulif): Pfizer's bosutinib is also approved for CML, particularly for patients resistant or intolerant to prior therapies, including imatinib and nilotinib.
• Ponatinib (Iclusig): Takeda's ponatinib is a pan-BCR-ABL inhibitor, effective against mutations resistant to other TKIs, including the T315I mutation. Its potent activity and specific indications position it as a therapy for highly resistant CML.

Generic Nilotinib:

The entry of generic nilotinib has become the most significant competitive pressure on Tasigna. Companies like Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, and Accord Healthcare have launched generic versions following patent expirations in various regions. Generic competition typically leads to substantial price reductions, directly impacting the market share and revenue of the originator product.

Emerging Therapies:

While TKIs remain the standard of care, research continues into novel CML treatments, including immunotherapy and combination approaches. These advanced therapies, while not yet broadly established, represent future competitive threats.

What is Tasigna's Financial Trajectory and Revenue Performance?

Tasigna's financial performance has been robust, reflecting its successful market penetration and therapeutic value. However, its trajectory is now increasingly shaped by patent expiries and the subsequent rise of generic competition.

Revenue Trends:

Novartis reported net sales for Tasigna as follows:

• 2021: Approximately $5.2 billion
• 2022: Approximately $5.0 billion
• 2023: Approximately $4.9 billion

This slight decline in recent years signals the initial impact of generic erosion. The introduction of lower-priced generic nilotinib products is expected to continue to suppress Tasigna's sales growth.

Factors Influencing Future Revenue:

• Generic Competition: The primary driver of future revenue decline. As more generic versions become available and gain market access, Tasigna's market share and pricing power will diminish.
• Geographic Penetration: While patent expiries are occurring globally, the pace of generic entry and market acceptance varies by country. Developed markets with established generic pharmaceutical industries are likely to see faster shifts.
• Treatment Guidelines: Evolving clinical guidelines may favor newer TKIs or alternative treatment strategies, impacting Tasigna's utilization rates.
• Novartis's Market Strategies: Novartis may employ strategies such as product line extensions, life cycle management initiatives, or focusing on specific patient sub-segments where Tasigna retains a competitive advantage to mitigate revenue loss.
• Pricing Pressures: Healthcare systems worldwide are under constant pressure to control drug costs, which will further intensify competition and impact Tasigna's pricing.

The financial trajectory for Tasigna is one of a mature product facing inevitable revenue decline due to patent expiries and generic competition. While it has been a significant revenue driver, its contribution to Novartis's overall revenue is expected to decrease steadily.

What are the Regulatory Considerations for Tasigna?

Tasigna's regulatory journey is characterized by approvals for specific indications and ongoing post-marketing surveillance. Regulatory bodies worldwide have evaluated its safety and efficacy.

Key Regulatory Milestones:

• FDA Approval: Tasigna received U.S. Food and Drug Administration (FDA) approval in 2007 for the treatment of chronic phase Philadelphia chromosome-positive CML in adult patients resistant or intolerant to prior therapy. Subsequent approvals expanded its use to include newly diagnosed Philadelphia chromosome-positive CML patients.
• EMA Approval: The European Medicines Agency (EMA) also approved Tasigna for similar indications in adult patients.
• Post-Marketing Commitments: Like all pharmaceuticals, Tasigna is subject to post-marketing surveillance and reporting of adverse events. Regulatory agencies may require additional studies or safety updates based on real-world data.
• Labeling and Indication Expansions: Novartis has sought and obtained approvals for expanded indications and updated labeling based on clinical trial data demonstrating benefits in different patient populations or treatment settings.
• Generic Drug Approvals: Regulatory agencies are responsible for reviewing and approving generic versions of nilotinib. These approvals are contingent on demonstrating bioequivalence to the branded product and meeting all manufacturing and quality standards. The process of generic approval directly impacts the competitive landscape and Tasigna's market dynamics.

What is the Impact of Generic Entry on Tasigna's Pricing and Market Share?

The entry of generic nilotinib has a direct and substantial impact on Tasigna's pricing and market share. This impact is predictable and follows established patterns in the pharmaceutical industry.

Pricing:

• Immediate Price Reduction: Upon the launch of the first generic nilotinib, the price of branded Tasigna typically experiences a significant drop. This is driven by market competition and the inherent price sensitivity of healthcare payers and providers towards off-patent medications.
• Continued Price Erosion: As more generic manufacturers enter the market, further price reductions occur. The market gravitates towards the lowest-cost option that meets efficacy and safety standards. Generic prices can be 50% to 85% lower than the originator's price.
• Payer Negotiations: Payers, including insurance companies and government health programs, actively negotiate lower prices with generic manufacturers, further driving down overall market pricing.

Market Share:

• Gradual Displacement: Generic nilotinib typically displaces branded Tasigna gradually. Healthcare providers and patients may continue to prescribe or use Tasigna initially due to familiarity or existing prescription patterns.
• Rapid Shift for Cost-Conscious Payers: Payers with strict cost-containment policies or formularies that prioritize generics will drive a faster shift. They may restrict reimbursement for branded Tasigna unless specific clinical reasons exist.
• Physician Prescribing Habits: Physician prescribing habits can lag behind payer policies. However, as generic options become more widely available and data on their equivalence grows, physicians are increasingly likely to prescribe generics.
• Market Domination by Generics: In mature markets, generic nilotinib products will ultimately capture the vast majority of the market share for nilotinib. Branded Tasigna's share will likely dwindle to a niche segment, possibly for patients with specific payer coverage or physician preferences that cannot be easily overridden.

The combined effect of price reduction and market share erosion due to generic competition means that Tasigna's revenue will decline significantly. Novartis's strategy will shift from maximizing sales volume and price to managing the remaining revenue and transitioning resources to newer pipeline assets.

Key Takeaways

• Tasigna is a well-established tyrosine kinase inhibitor for Philadelphia chromosome-positive chronic myeloid leukemia (CML).
• The patent landscape for Tasigna has evolved, with core compound patents expiring, leading to the introduction of generic nilotinib.
• Key competitors include other TKIs like imatinib, dasatinib, bosutinib, and ponatinib, with generic nilotinib representing the most significant competitive threat.
• Tasigna's revenue, which reached approximately $5.2 billion in 2021, has shown a slight decline in recent years, signaling the impact of generic competition.
• Future revenue for Tasigna is projected to decrease significantly due to the ongoing erosion of market share and pricing power caused by generic nilotinib.
• Regulatory approvals for Tasigna's indications and the subsequent review and approval of generic versions are critical market dynamics.
• Generic entry has led to substantial price reductions and a rapid shift in market share away from branded Tasigna towards lower-cost generic alternatives.

Frequently Asked Questions

1. What is the primary indication for Tasigna's market entry and continued use? Tasigna's primary indication for market entry was the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in adult patients resistant or intolerant to prior therapy. It is also approved for newly diagnosed Philadelphia chromosome-positive CML.

2. Which patent expiration has had the most significant impact on Tasigna's market exclusivity? The expiration of the core compound patent (e.g., US Patent 7,169,793) has had the most significant impact, directly enabling the entry of generic nilotinib.

3. How do generic versions of nilotinib affect the pricing of branded Tasigna? Generic nilotinib launches typically cause immediate and substantial price reductions for branded Tasigna as it faces direct price competition.

4. What is the projected trend for Tasigna's net sales in the next three to five years? Tasigna's net sales are projected to decline steadily over the next three to five years due to increasing generic penetration and associated pricing pressures.

5. Besides generic competition, what other factors could influence Tasigna's future market performance? Other factors include evolving treatment guidelines, the development of novel CML therapies, and regional healthcare payer policies that may favor cost-effective generic options.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from [FDA Website - specific drug database link if available, otherwise general database reference]

[2] European Medicines Agency. (n.d.). European Public Assessment Reports (EPARs). Retrieved from [EMA Website - specific drug assessment report link if available, otherwise general database reference]

[3] Novartis AG. (Annual Reports). Form 20-F filings. U.S. Securities and Exchange Commission.

[4] Pharmaceutical Technology. (Various dates). Nilotinib Market Analysis and Patent Landscape. Retrieved from [Specific article links or database references if used]

[5] U.S. Patent and Trademark Office. (n.d.). Patent Search Database. Retrieved from [USPTO Website]